Starsource Multitrade Ltd
NSE: BSE: 506365
₹123.80
(4.43%)
Fri, 08 May 2026, 04:36 pm
Market Cap0
PE Ratio0
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KStarsource Multitrade Analysis
dividend
- Unable to evaluate Chemo Pharma Laboratories's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Chemo Pharma Laboratories's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Chemo Pharma Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Chemo Pharma Laboratories is profitable, therefore cash runway is not a concern.
- Chemo Pharma Laboratories is profitable, therefore cash runway is not a concern.
- Chemo Pharma Laboratories has no debt, it does not need to be covered by operating cash flow.
- Chemo Pharma Laboratories has no debt, it does not need to be covered by short term assets.
- Chemo Pharma Laboratories has no long term commitments.
- Chemo Pharma Laboratories currently has no debt however we can't compare to 5 years ago as we have no data for that period.
- Chemo Pharma Laboratories has no debt, therefore coverage of interest payments is not a concern.
- Chemo Pharma Laboratories has no debt.
- Low level of unsold assets.
management
- The average tenure for the Chemo Pharma Laboratories board of directors is less than 3 years, this suggests a new board.
misc
- Chemo Pharma Laboratories is not covered by any analysts.
past
- Chemo Pharma Laboratories's 1-year earnings growth exceeds its 5-year average (320.1% vs 15.8%)
- Chemo Pharma Laboratories's year on year earnings growth rate has been positive over the past 5 years, however the most recent earnings are below average.
- Chemo Pharma Laboratories used its assets more efficiently than the IN Diversified Financial industry average last year based on Return on Assets.
- Chemo Pharma Laboratories has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Chemo Pharma Laboratories's earnings growth has exceeded the IN Diversified Financial industry average in the past year (320.1% vs 13.5%).
- Chemo Pharma Laboratories has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
value
- Chemo Pharma Laboratories is good value based on assets compared to the IN Diversified Financial industry average.
- Chemo Pharma Laboratories is good value based on earnings compared to the IN Diversified Financial industry average.
- Chemo Pharma Laboratories is good value based on earnings compared to the India market.
- 506365 outperformed the Diversified Financial industry which returned -37.3% over the past year.
- 506365 outperformed the Market in India which returned -14.5% over the past year.
- BSE:506365 is down -5.2% underperforming the Diversified Financial industry which returned 10.8% over the past month.
- BSE:506365 is down -5.2% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800